Fiducient Advisors’s Idexx Laboratories IDXX Stock Holding History

Fiducient Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,399	Closed	-$1.39M	–	102
2022 Q4	$1.39M	Buy	+3,399	New	+$1.32M	0.41%	32

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fiducient Advisors's IDXX Position: Q1 2023 in Review

Fiducient Advisors sold out of Idexx Laboratories (IDXX) in Q1 2023, closing a stake of 3,399 shares — an estimated $1.39M sold.

Fiducient Advisors first reported a position in IDXX in Q4 2022 and held it in 1 quarter. The position peaked at $1.39M in Q4 2022. 1,055 funds tracked by Wall St. Rank hold IDXX as of Q1 2023.

Fiducient Advisors reported no remaining Idexx Laboratories position as of Q1 2023 after selling out during the quarter.
Fiducient Advisors sold 3,399 Idexx Laboratories shares in Q1 2023, an estimated $1.39M.
Fiducient Advisors first reported a position in Idexx Laboratories in Q4 2022 and held it in 1 quarter.
Fiducient Advisors's Idexx Laboratories position peaked at $1.39M in Q4 2022.
1,055 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2023.

Based on Fiducient Advisors's 13F filing for Q1 2023, filed 8 May 2023.